Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitamaquine vs Amphotericin B in Visceral Leishmaniasis
NCT00381394Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sitamaquine in visceral leishmaniasis (VL) (2 arms), sponsored by GSK. Primary endpoints: Area under the concentration-time curve over the dosing interval at Day 21, Maximum plasma concentration at Day 21 and 2 more. Started Aug 2006; status: completed.
02
Drugs
sitamaquine
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT00381394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381394.